[1]Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies[J]. Nat Rev Immunol, 2010, 10(5): 345-352.
[2]Mathas S, Rickers A, Bommert K, et al. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways[J]. Cancer Res, 2000, 60(24): 7170-7176.
[3]Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy[J]. Oncogene, 2000, 19(56): 6550-6565.
[4]Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer[J]. J Clin Oncol, 2012, 30(13): 1505-1512.
[5]Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.
[6]Birrer MJ, Moore KN, Betella I, et al. Antibody-drug conjugate-based therapeutics: state of the science[J]. J Natl Cancer Inst, 2019, doi: 10.1093/jnci/djz035. [Epub ahead of print].
[7]Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia[J]. Clin Cancer Res, 2001, 7(6): 1490-1496.
[8]Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse[J]. J Clin Oncol, 2001, 19(13): 3244-3254.
[9]Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation[J]. Cancer, 2001, 92(2): 406-413.
[10]Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia[J]. Blood, 2013, 121(24): 4854-4860.
[11]Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials[J]. Lancet Oncol, 2014, 15(9): 986-996.
[12]Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates[J]. MAbs, 2016, 8(4): 659-671.
[13]Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy[J]. Lancet Oncol, 2016, 17(6): e254-e262.
[14]Chari RV. Expanding the reach of antibody-drug conjugates[J]. ACS Med Chem Lett, 2016, 7(11): 974-976.
[15]Schumacher D, Hackenberger CP, Leonhardt H, et al. Current status: site-specific antibody drug conjugates[J]. J Clin Immunol, 2016, 36 Suppl 1: 100-107.
[16]Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential[J]. Clin Cancer Res, 2011, 17(20): 6389-6397.
[17]Singh SK, Luisi DL, Pak RH. Antibody-drug conjugates: design, formulation and physicochemical stability[J]. Pharm Res, 2015, 32(11): 3541-3571.
[18]Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy[J]. J Clin Oncol, 2011, 29(4): 398-405.
[19]Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine[J]. Gynecol Oncol, 2017, 147(2): 402-407.
[20]Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: A review[J]. Adv Ther, 2017, 34(5): 1015-1035.
[21]Perica K. Adoptive T cell immunotherapy for cancer[J]. Rambam Maimonides Med J, 2015, 6(1): e0004.
[22]Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230): 62-68.
[23]Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies[J]. Front Oncol, 2018, 8: 315.
[24]Davda J, Declerck P, Hu-Lieskovan S, et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics[J]. J Immunother Cancer, 2019, 7(1): 105.
[25]Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723.
[26]Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med, 2011, 364(26): 2517-2526.
[27]Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy[J]. Lancet Oncol, 2016, 17(12): e542-e551.
[28]Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[29]Garon EB. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028.
[30]Larkin J. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1): 23-34.
[31]Cheng W, Fu D, Xu F, et al. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy[J]. Oncogenesis, 2018, 7(1): 2.
[32]Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers[J]. Exp Mol Med, 2018, 50(12): 165.
[33]Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330.
[34]Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance[J]. J Cell Sci, 2012, 125(Pt 23): 5591-5596.
[35]Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment[J]. Cancer Lett, 2016, 370(1): 85-90.
[36]Hasmim M, Messai Y, Ziani L, et al. Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress[J]. Front Immunol, 2015, 6: 482.
[37]Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection[J]. Microvasc Res, 1989, 37(1): 77-104.
[38]Couzin-Frankel J. Autoimmune diseases surface after cancer treatment[J]. Science, 2017, 358(6365): 852.
[39]Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors[J]. BioDrugs, 2016, 30(6): 571-584.
[40]Joshi MN, Whitelaw BC, Palomar MT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review[J]. Clin Endocrinol (Oxf), 2016, 85(3): 331-339.
[44]O'Day SJ. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study[J]. Ann Oncol, 2010, 21(8): 1712-1717.
[42]Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer[J]. N Engl J Med, 2005, 353(25): 2654-2666.
[43]De Angulo G. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies[J]. Cancer, 2008, 112(2): 407-415.
[44]Simeone E, Gentilcore G, Giannarelli D, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma[J]. Cancer Immunol Immunother, 2014, 63(7): 675-683.
[45]Cesano A, Warren S. Bringing the next generation of immuno-oncology biomarkers to the clinic[J]. Biomedicines, 2018. 6(1), doi: 10.3390/biomedicines6010014.
[46]Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1[J]. Cancer Res, 2015, 75(11): 2139-2145.
[47]McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280): 1463-1469.
[48]Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer[J]. Cancer Discov, 2017, 7(3): 264-276.
[49]Ascierto ML, Kmieciak M, Idowu MO, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients[J]. Breast Cancer Res Treat, 2012, 131(3): 871-880.
[50]Marwitz S, Scheufele S, Perner S, et al. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression[J]. Clin Epigenetics, 2017, 9: 51.
[51]Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential[J]. Ther Adv Med Oncol, 2015, 7(2): 97-106.
[52]Baumeister SH. Coinhibitory pathways in immunotherapy for cancer[J]. Annu Rev Immunol, 2016, 34: 539-573.
[53]Khalil DN. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy[J]. Nat Rev Clin Oncol, 2016, 13(6): 394.
[54]Shindo Y, Yoshimura K, Kuramasu A, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor[J]. Anticancer Res, 2015, 35(1): 129-136.
[55]Sharabi AB, Tran PT, Lim M, et al. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment[J]. Oncology (Williston Park), 2015, 29(5): 331-340.
[56]Mazzone R, Zwergel C, Mai A, et al. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy[J]. Clin Epigenetics, 2017, 9: 59.
[57]Tchekmedyian N. Propelling immunotherapy combinations into the clinic[J]. Oncology (Williston Park), 2015, 29(12): 990-1002.
[58]Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer[J]. Trends Immunol, 2016, 37(7): 462-476.
[59]Mouraviev V, Mariados N, Albala D, et al. The rationale for optimal combination therapy with sipuleucel-T for patients with castration-resistant prostate cancer[J]. Rev Urol, 2014, 16(3): 122-130.
[60]Ali OA, Lewin SA, Dranoff G, et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication[J]. Cancer Immunol Res, 2016, 4(2): 95-100.
[61]Nunez-Prado N. The coming of age of engineered multivalent antibodies[J]. Drug Discov Today, 2015, 20(5): 588-594.
[62]Fan G. Bispecific antibodies and their applications[J]. J Hematol Oncol, 2015, 8: 130.
[63]May C, Sapra P, Gerber HP. Advances in bispecific biotherapeutics for the treatment of cancer[J]. Biochem Pharmacol, 2012, 84(9): 1105-1112.
[64]Suryadevara CM, Gedeon PC, Sanchez-Perez L, et al. Are BiTEs the "missing link" in cancer therapy[J]? Oncoimmunology, 2015, 4(6): e1008339.
[65]Trivedi A. Clinical pharmacology and translational aspects of bispecific antibodies[J]. Clin Transl Sci, 2017, 10(3): 147-162.
[66]Center for Drug Evaluation and Research.Codevelopment of two or more new investigational drugs for use in combination[EB/OL][2019-11-14]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/codevelopment-two-or-more-new-investigational-drugs-use-combination.
[67]van Steeg TJ, Bergmann KR, Dimasi N, et al. The application of mathematical modelling to the design of bispecific monoclonal antibodies[J]. MAbs, 2016, 8(3): 585-592.
[68]Brinkmann U, Kontermann RE. The making of bispecific antibodies[J]. MAbs, 2017, 9(2): 182-212.
[69]Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies[J]. Acta Pharmacol Sin, 2005, 26(6): 649-658.
[70]Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer[J]. Nat Rev Cancer, 2012, 12(4): 278-287.
[71]Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy[J]. Semin Immunol, 2008, 20(5): 276-285.
[72]Mazor Y. Insights into the molecular basis of a bispecific antibody's target selectivity[J]. MAbs, 2015, 7(3): 461-469.
[73]Kozlowski S, Woodcock J, Midthun K, et al. Developing the nation's biosimilars program[J]. N Engl J Med, 2011, 365(5): 385-388.
[74]Finkelstein JB, In US. Biosimilars still await FDA decision[J]. J Natl Cancer Inst, 2006, 98(7): 435. |